Hementin-Like Protein (HLP-1)
Fibrinogenolytic / anti-platelet protein homologous to hementin — disrupts platelet aggregation.
- Hementin-Like Protein (HLP-1)80 kDa
- Hementerin80 kDa
- Hementin80 kDa
- Leech Collagenase70 kDa
- Haemadipsa yanyuanensis Progranulin (Hy-PGRN)70 kDa
- Leech Apyrase67 kDa
- Calin65 kDa
- Hyaluronidase60 kDa
- Antithrombin III binding protein58 kDa
- Collagenolytic Fibrinolysin55 kDa
- Leech Thrombospondin-Like Protein50 kDa
- LHyal (Leech Hyaluronidase)50 kDa
Mechanistic Evidence Box
Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.- Page type
- Compound profile
- Evidence type
- Preclinical / biochemical characterization
- Evidence level
- In vitro
- Drug vs leech
- Purified natural compound
- Safety domains
- Bleeding
Clinical translation limit
HLP-1 is documented mechanistically only; no human evidence. Homology to hementin does NOT establish clinical efficacy, and no FDA-approved derivative exists.
Molecular Profile
- Category
- Antiplatelet
- Evidence tier
- Preclinical
- Molecular weight
- 80,000 Da
- Source species
- Haementeria-related species
- Discovered
- 2006
Biological Targets
- → fibrinogen
- → platelet aggregation
External Resources
Related Antiplatelet Compounds
Calin
Anti-platelet adhesion protein that blocks von Willebrand factor–collagen binding.
Saratin
Anti-platelet adhesion protein blocking collagen-mediated platelet activation.
Decorsin
RGD-containing peptide that inhibits the platelet GP IIb/IIIa receptor; the drug eptifibatide was modelled on snake-venom barbourin, not on decorsin.
Ornatin
RGD-peptide GP IIb/IIIa antagonist — sister molecule to decorsin from a different leech species.